Efficacy of intravenous vitamin-D selective receptor activator [Paricalcitol] in management of secondary Hyperparathyroidism in Hemodialysis patients, single center experience
Egyptian Journal of Hospital Medicine [The]. 2015; 61 (October): 522-528
en Inglés
| IMEMR
| ID: emr-173909
ABSTRACT
Background:
secondary hyperparathyroidism [SHPT], a complication of chronic kidney disease [CKD] and is characterized by not only increased serum levels of intact parathyroid hormone [iPTH], but also may cause skeletal and cardiovascular complications. Deficiency of calcitriol [1, 25-hydroxy vitamin D] caused by impaired renal function, a main factor in the pathogenesis and pathophysiology of secondary hyperparathyroidism [SHPT] is associated with poor outcomes in hemodialysis patients. Therapy with vitamin D receptor [VDR] activators, including calcitriol or the selective VDR activator paricalcitol, has been associated with improved survival in patients with CKD on hemodialysis
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Vitamina D
/
Diálisis Renal
/
Receptores de Calcitriol
/
Manejo de la Enfermedad
/
Administración Intravenosa
/
Hiperparatiroidismo Secundario
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Egypt. J. Hosp. Med.
Año:
2015
Similares
MEDLINE
...
LILACS
LIS